{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:38:51Z","timestamp":1792543131255,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY031952, R01EY031360, R01EY030151, P30EY026877, and R38EY037090"],"award-info":[{"award-number":["R01EY031952, R01EY031360, R01EY030151, P30EY026877, and R38EY037090"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["449589"],"award-info":[{"award-number":["449589"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["DGECR-2019-00112"],"award-info":[{"award-number":["DGECR-2019-00112"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01757-6","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:11:06Z","timestamp":1782850266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Paired longitudinal tear proteomics reveals persistent ocular surface dysregulation after teprotumumab therapy in thyroid eye disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Gabriel","family":"Velez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia-Han","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Amarikwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3429-4188","authenticated-orcid":false,"given":"Antoine","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-1741","authenticated-orcid":false,"given":"Vinit B.","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"1757_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith, T. J. & Heged\u00fcs, L. Graves\u2019 disease. N. Engl. J. Med. 375, 1552\u20131565 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14296","volume":"93","author":"YH Chin","year":"2020","unstructured":"Chin, Y. H. et al. Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review. Clin. Endocrinol. 93, 363\u2013374 (2020).","journal-title":"Clin. Endocrinol."},{"key":"1757_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn, R. S. Graves\u2019 ophthalmopathy. N. Engl. J. Med. 362, 726\u2013738 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","volume":"100","author":"JJ Khong","year":"2016","unstructured":"Khong, J. J., McNab, A. A., Ebeling, P. R., Craig, J. E. & Selva, D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br. J. Ophthalmol. 100, 142\u2013150 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"1757_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/02713683.2010.526285","volume":"36","author":"C G\u00fcrdal","year":"2011","unstructured":"G\u00fcrdal, C. et al. Ocular surface and dry eye in Graves\u2019 disease. Curr. Eye Res. 36, 8\u201313 (2011).","journal-title":"Curr. Eye Res."},{"key":"1757_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar, S. et al. Teprotumumab for the treatment of chronic thyroid eye disease. EYE 36, 1553\u20131559 (2022).","journal-title":"EYE"},{"key":"1757_CR7","doi-asserted-by":"publisher","first-page":"bvab034","DOI":"10.1210\/jendso\/bvab034","volume":"5","author":"C Dosiou","year":"2021","unstructured":"Dosiou, C. & Kossler, A. L. Thyroid eye disease: navigating the new treatment landscape. J. Endocr. Soc. 5, bvab034 (2021).","journal-title":"J. Endocr. Soc."},{"key":"1757_CR8","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui, S. et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J. Immunol. 181, 4397\u20134405 (2008).","journal-title":"J. Immunol."},{"key":"1757_CR9","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1210\/en.2011-0231","volume":"152","author":"EJ Gallagher","year":"2011","unstructured":"Gallagher, E. J. & LeRoith, D. Minireview: IGF, insulin, and cancer. Endocrinology 152, 2546\u20132551 (2011).","journal-title":"Endocrinology"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","volume":"178","author":"RS Douglas","year":"2007","unstructured":"Douglas, R. S., Gianoukakis, A. G., Kamat, S. & Smith, T. J. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis. J. Immunol. 178, 3281\u20133287 (2007).","journal-title":"J. Immunol."},{"key":"1757_CR11","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith, T. J. et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 376, 1748\u20131761 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341\u2013352 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ceo.14208","volume":"51","author":"S Ugradar","year":"2023","unstructured":"Ugradar, S. et al. Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clin. Experiment. Ophthalmol. 51, 339\u2013348 (2023).","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"1757_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly, G. J., Douglas, R. S., Holt, R. J., Sile, S. & Smith, T. J. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 9, 360\u2013372 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1757_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/IOP.0000000000002531","volume":"40","author":"TR Rosenblatt","year":"2024","unstructured":"Rosenblatt, T. R. et al. Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthal. Plast. Reconstr. Surg. 40, 187\u2013191 (2024).","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"1757_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IOP.0b013e31823c4a3a","volume":"28","author":"MA Harris","year":"2012","unstructured":"Harris, M. A., Realini, T., Hogg, J. P. & Sivak-Callcott, J. A. CT dimensions of the lacrimal gland in Graves orbitopathy. Ophthal. Plast. Reconstr. Surg. 28, 69\u201372 (2012).","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"1757_CR17","doi-asserted-by":"crossref","unstructured":"Zhao, R.-X. et al. The value of SPECT\/CT imaging of lacrimal glands as a means of assessing the activity of Graves\u2019 orbitopathy. Endocr. Connect. 11, e210590 (2022).","DOI":"10.1530\/EC-21-0590"},{"key":"1757_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/IOP.0000000000000015","volume":"30","author":"CM Bingham","year":"2014","unstructured":"Bingham, C. M. et al. Calculated computed tomography volumes of lacrimal glands and comparison to clinical findings in patients with thyroid eye disease. Ophthal. Plast. Reconstr. Surg. 30, 116\u2013118 (2014).","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"1757_CR19","first-page":"322","volume":"44","author":"C Jiang","year":"2019","unstructured":"Jiang, C. et al. Efficacy of 99mTc-DTPA orbital SPECT\/CT on the evaluation of lacrimal gland inflammation in patients with thyroid associated ophthalmopathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban 44, 322\u2013328 (2019).","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"1757_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","volume":"329","author":"RS Bahn","year":"1993","unstructured":"Bahn, R. S. & Heufelder, A. E. Pathogenesis of Graves\u2019 ophthalmopathy. N. Engl. J. Med. 329, 1468\u20131475 (1993).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1210\/jc.2010-2329","volume":"96","author":"L Bartalena","year":"2011","unstructured":"Bartalena, L. The dilemma of how to manage Graves\u2019 hyperthyroidism in patients with associated orbitopathy. J. Clin. Endocrinol. Metab. 96, 592\u2013599 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1757_CR22","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena, L. & Tanda, M. L. Clinical practice. Graves\u2019 ophthalmopathy. N. Engl. J. Med. 360, 994\u20131001 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2265.1990.tb00897.x","volume":"32","author":"TC Chang","year":"1990","unstructured":"Chang, T. C., Huang, K. M., Chang, T. J. & Lin, S. L. Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves\u2019 disease. Clin. Endocrinol. 32, 551\u2013558 (1990).","journal-title":"Clin. Endocrinol."},{"key":"1757_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1395-3907.2004.00268.x","volume":"82","author":"AK Eckstein","year":"2004","unstructured":"Eckstein, A. K. et al. Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol. Scand. 82, 291\u2013297 (2004).","journal-title":"Acta Ophthalmol. Scand."},{"key":"1757_CR25","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/archopht.124.10.1451","volume":"124","author":"GRC Baker","year":"2006","unstructured":"Baker, G. R. C. et al. Altered tear composition in smokers and patients with Graves ophthalmopathy. Arch. Ophthalmol. 124, 1451\u20131456 (2006).","journal-title":"Arch. Ophthalmol."},{"key":"1757_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0029-1214413","volume":"41","author":"R Okrojek","year":"2009","unstructured":"Okrojek, R., Grus, F. H., Matheis, N. & Kahaly, G. J. Proteomics in autoimmune thyroid eye disease. Horm. Metab. Res. 41, 465\u2013470 (2009).","journal-title":"Horm. Metab. Res."},{"key":"1757_CR27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1089\/thy.2012.0119","volume":"22","author":"N Matheis","year":"2012","unstructured":"Matheis, N., Okrojek, R., Grus, F. H. & Kahaly, G. J. Proteomics of tear fluid in thyroid-associated orbitopathy. Thyroid. 22, 1039\u20131045 (2012).","journal-title":"Thyroid."},{"key":"1757_CR28","first-page":"2777","volume":"251","author":"K-C Cheng","year":"2013","unstructured":"Cheng, K.-C. et al. Proteomic analysis of the differences in orbital protein expression in thyroid orbitopathy. Arbeitsphysiologie 251, 2777\u20132787 (2013).","journal-title":"Arbeitsphysiologie"},{"key":"1757_CR29","doi-asserted-by":"publisher","first-page":"E1523","DOI":"10.1210\/jc.2015-2976","volume":"100","author":"N Matheis","year":"2015","unstructured":"Matheis, N. et al. Proteomics of orbital tissue in thyroid-associated orbitopathy. J. Clin. Endocrinol. Metab. 100, E1523\u201330 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1757_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/bjophthalmol-2015-306634","volume":"99","author":"K-C Cheng","year":"2015","unstructured":"Cheng, K.-C. et al. Proteomic surveillance of putative new autoantigens in thyroid orbitopathy. Br. J. Ophthalmol. 99, 1571\u20131576 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"1757_CR31","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1167\/iovs.15-16699","volume":"56","author":"N Matheis","year":"2015","unstructured":"Matheis, N. et al. Proteomics differentiate between thyroid-associated orbitopathy and dry eye syndrome. Invest. Ophthalmol. Vis. Sci. 56, 2649\u20132656 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26700-1","volume":"8","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves\u2019 disease and orbitopathy. Sci. Rep. 8, 8386 (2018).","journal-title":"Sci. Rep."},{"key":"1757_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jprot.2017.09.001","volume":"170","author":"E Kishazi","year":"2018","unstructured":"Kishazi, E. et al. Thyroid-associated orbitopathy and tears: a proteomics study. J. Proteomics 170, 110\u2013116 (2018).","journal-title":"J. Proteomics"},{"key":"1757_CR34","doi-asserted-by":"crossref","unstructured":"Ma, J. Y. W., Sze, Y. H., Bian, J. F. & Lam, T. C. Critical role of mass spectrometry proteomics in tear biomarker discovery for multifactorial ocular diseases (Review). Int. J. Mol. Med. 47, 83 (2021).","DOI":"10.3892\/ijmm.2021.4916"},{"key":"1757_CR35","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ijms22031115","volume":"22","author":"J-S Han","year":"2021","unstructured":"Han, J.-S. et al. Tear-derived exosome proteins are increased in patients with Thyroid eye disease. Int. J. Mol. Sci. 22, 1115 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1757_CR36","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1167\/iovs.11-9054","volume":"53","author":"J-F Huang","year":"2012","unstructured":"Huang, J.-F., Zhang, Y., Rittenhouse, K. D., Pickering, E. H. & McDowell, M. T. Evaluations of tear protein markers in dry eye disease: repeatability of measurement and correlation with disease. Invest. Ophthalmol. Vis. Sci. 53, 4556\u20134564 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits, M. P., Prummel, M. F., Wiersinga, W. M. & Koornneef, L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin. Endocrinol. 47, 9\u201314 (1997).","journal-title":"Clin. Endocrinol."},{"key":"1757_CR38","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena, L. et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur. J. Endocrinol. 185, G43\u2013G67 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"1757_CR39","doi-asserted-by":"publisher","first-page":"104146","DOI":"10.1016\/j.xpro.2025.104146","volume":"6","author":"G-H Ngo","year":"2025","unstructured":"Ngo, G.-H. et al. Protocol to extract tear fluid for proteomics using Schirmer strips. STAR Protoc 6, 104146 (2025).","journal-title":"STAR Protoc"},{"key":"1757_CR40","first-page":"13.20.1","volume":"Chapter 13","author":"M Bern","year":"2012","unstructured":"Bern, M., Kil, Y. J. & Becker, C. Byonic: advanced peptide and protein identification software. Curr. Protoc. Bioinformatics Chapter 13, 13.20.1\u201313.20.14 (2012).","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"1757_CR41","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/nprot.2016.136","volume":"11","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11, 2301\u20132319 (2016).","journal-title":"Nat. Protoc."},{"key":"1757_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-0716-1967-4_10","volume":"2426","author":"J Gregori","year":"2023","unstructured":"Gregori, J., S\u00e1nchez, \u00c0 & Villanueva, J. MsmsEDA & msmsTests: label-free differential expression by spectral counts. Methods Mol. Biol. 2426, 197\u2013242 (2023).","journal-title":"Methods Mol. Biol."},{"key":"1757_CR43","doi-asserted-by":"crossref","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","DOI":"10.1186\/gb-2010-11-3-r25"},{"key":"1757_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1757_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jprot.2016.05.006","volume":"150","author":"M Azkargorta","year":"2017","unstructured":"Azkargorta, M., Soria, J., Acera, A., Iloro, I. & Elortza, F. Human tear proteomics and peptidomics in ophthalmology: toward the translation of proteomic biomarkers into clinical practice. J. Proteomics 150, 359\u2013367 (2017).","journal-title":"J. Proteomics"},{"key":"1757_CR46","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/bioinformatics\/btp053","volume":"25","author":"DJ McCarthy","year":"2009","unstructured":"McCarthy, D. J. & Smyth, G. K. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics 25, 765\u2013771 (2009).","journal-title":"Bioinformatics"},{"key":"1757_CR47","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1016\/j.jprot.2012.04.053","volume":"75","author":"L Zhou","year":"2012","unstructured":"Zhou, L. et al. In-depth analysis of the human tear proteome. J. Proteomics 75, 3877\u20133885 (2012).","journal-title":"J. Proteomics"},{"key":"1757_CR48","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513\u20132526 (2014).","journal-title":"Mol. Cell. Proteomics"},{"key":"1757_CR49","doi-asserted-by":"publisher","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","volume":"39","author":"D Croft","year":"2011","unstructured":"Croft, D. et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 39, D691\u20137 (2011).","journal-title":"Nucleic Acids Res."},{"key":"1757_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"1757_CR51","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1757_CR52","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nmeth.2689","volume":"10","author":"M Griffith","year":"2013","unstructured":"Griffith, M. et al. DGIdb: mining the druggable genome. Nat. Methods 10, 1209\u20131210 (2013).","journal-title":"Nat. Methods"},{"key":"1757_CR53","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 52, D1265\u2013D1275 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1757_CR54","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1038\/s41375-021-01436-6","volume":"35","author":"EA Bruford","year":"2021","unstructured":"Bruford, E. A. et al. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia 35, 3040\u20133043 (2021).","journal-title":"Leukemia"},{"key":"1757_CR55","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.3390\/ijms23042307","volume":"23","author":"G Jones","year":"2022","unstructured":"Jones, G. et al. Comparison of different mass spectrometry workflows for the proteomic analysis of tear fluid. Int. J. Mol. Sci. 23, 2307 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1757_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.64.13.13","volume":"64","author":"A Guntermann","year":"2023","unstructured":"Guntermann, A. et al. Investigation of inter- and intra-day variability of tear fluid regarding flow rate, protein concentration as well as protein composition. Invest. Ophthalmol. Vis. Sci. 64, 13 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2022.101705","volume":"45","author":"CA-D Arroyo","year":"2022","unstructured":"Arroyo, C. A.-D. et al. Diurnal variation on tear stability and correlation with tear cytokine concentration. Cont. Lens Anterior Eye 45, 101705 (2022).","journal-title":"Cont. Lens Anterior Eye"},{"key":"1757_CR58","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.exer.2013.12.017","volume":"120","author":"MJ Benito","year":"2014","unstructured":"Benito, M. J. et al. Intra- and inter-day variation of cytokines and chemokines in tears of healthy subjects. Exp. Eye Res. 120, 43\u201349 (2014).","journal-title":"Exp. Eye Res."},{"key":"1757_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.65.3.2","volume":"65","author":"G Jones","year":"2024","unstructured":"Jones, G. et al. Unraveling the intraday variations in the tear fluid proteome. Invest. Ophthalmol. Vis. Sci. 65, 2 (2024).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR60","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1167\/iovs.16-20789","volume":"58","author":"TH Dohlman","year":"2017","unstructured":"Dohlman, T. H., Ding, J., Dana, R. & Chauhan, S. K. T cell-derived granulocyte-macrophage colony-stimulating factor contributes to dry eye disease pathogenesis by promoting CD11b+ myeloid cell maturation and migration. Invest. Ophthalmol. Vis. Sci. 58, 1330\u20131336 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR61","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.1167\/iovs.11-7655","volume":"52","author":"RM Corrales","year":"2011","unstructured":"Corrales, R. M. et al. Ocular mucin gene expression levels as biomarkers for the diagnosis of dry eye syndrome. Invest. Ophthalmol. Vis. Sci. 52, 8363\u20138369 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/gt.2012.56","volume":"20","author":"L Contreras-Ruiz","year":"2013","unstructured":"Contreras-Ruiz, L. et al. A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model. Gene Ther. 20, 467\u2013477 (2013).","journal-title":"Gene Ther."},{"key":"1757_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.exer.2015.03.016","volume":"134","author":"AAM Torricelli","year":"2015","unstructured":"Torricelli, A. A. M. et al. Epithelial basement membrane proteins perlecan and nidogen-2 are up-regulated in stromal cells after epithelial injury in human corneas. Exp. Eye Res. 134, 33\u201338 (2015).","journal-title":"Exp. Eye Res."},{"key":"1757_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31441-2","volume":"8","author":"J Wittmann","year":"2018","unstructured":"Wittmann, J. et al. Plasma gelsolin promotes re-epithelialization. Sci. Rep. 8, 13140 (2018).","journal-title":"Sci. Rep."},{"key":"1757_CR65","doi-asserted-by":"publisher","first-page":"15239","DOI":"10.3390\/ijms232315239","volume":"23","author":"Y-T Hsiao","year":"2022","unstructured":"Hsiao, Y.-T., Huang, Y.-T., Yu, H.-J., Fang, P.-C. & Kuo, M.-T. Tear proteomics approach to distinguishing primary from secondary Sj\u00f6gren\u2019s syndrome for dry eye patients with long-term instillation of eyedrops. Int. J. Mol. Sci. 23, 15239 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1757_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/srep05772","volume":"4","author":"B Li","year":"2014","unstructured":"Li, B. et al. Tear proteomic analysis of Sj\u00f6gren syndrome patients with dry eye syndrome by two-dimensional-nano-liquid chromatography coupled with tandem mass spectrometry. Sci. Rep. 4, 5772 (2014).","journal-title":"Sci. Rep."},{"key":"1757_CR67","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1021\/pr900686s","volume":"8","author":"L Zhou","year":"2009","unstructured":"Zhou, L. et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J. Proteome Res. 8, 4889\u20134905 (2009).","journal-title":"J. Proteome Res."},{"key":"1757_CR68","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig, J. P. et al. TFOS DEWS II definition and classification report. Ocul. Surf. 15, 276\u2013283 (2017).","journal-title":"Ocul. Surf."},{"key":"1757_CR69","doi-asserted-by":"publisher","first-page":"10386","DOI":"10.3390\/ijms221910386","volume":"22","author":"Y Mun","year":"2021","unstructured":"Mun, Y., Hwang, J. S. & Shin, Y. J. Role of neutrophils on the ocular surface. Int. J. Mol. Sci. 22, 10386 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1757_CR70","doi-asserted-by":"crossref","unstructured":"Bader, G. D. & Hogue, C. W. V. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4, 2 (2003).","DOI":"10.1186\/1471-2105-4-2"},{"key":"1757_CR71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic, V. et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N. Engl. J. Med. 392, 531\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1757_CR72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","volume":"55","author":"SJ Kim","year":"2010","unstructured":"Kim, S. J., Flach, A. J. & Jampol, L. M. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv. Ophthalmol. 55, 108\u2013133 (2010).","journal-title":"Surv. Ophthalmol."},{"key":"1757_CR73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jdermsci.2007.06.006","volume":"48","author":"DJ Marble","year":"2007","unstructured":"Marble, D. J., Gordon, K. B. & Nickoloff, B. J. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J. Dermatol. Sci. 48, 87\u2013101 (2007).","journal-title":"J. Dermatol. Sci."},{"key":"1757_CR74","first-page":"613086","volume":"2013","author":"R Prieto-P\u00e9rez","year":"2013","unstructured":"Prieto-P\u00e9rez, R. et al. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013, 613086 (2013).","journal-title":"Autoimmune Dis."},{"key":"1757_CR75","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/art.1780331121","volume":"33","author":"R Segal","year":"1990","unstructured":"Segal, R., Yaron, M. & Tartakovsky, B. Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum. 33, 1745\u20131748 (1990).","journal-title":"Arthritis Rheum."},{"key":"1757_CR76","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13075-019-2064-y","volume":"21","author":"EC de Moel","year":"2019","unstructured":"de Moel, E. C. et al. Circulating calprotectin (S100A8\/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Res. Ther. 21, 268 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1757_CR77","first-page":"988","volume":"15","author":"M Chow","year":"2016","unstructured":"Chow, M. et al. Effect of adalimumab on gene expression profiles of psoriatic skin and blood. J. Drugs Dermatol. 15, 988\u2013994 (2016).","journal-title":"J. Drugs Dermatol."},{"key":"1757_CR78","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1152\/physrev.00013.2002","volume":"82","author":"M Fill","year":"2002","unstructured":"Fill, M. & Copello, J. A. Ryanodine receptor calcium release channels. Physiol. Rev. 82, 893\u2013922 (2002).","journal-title":"Physiol. Rev."},{"key":"1757_CR79","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","volume":"128","author":"A Slobodnick","year":"2015","unstructured":"Slobodnick, A., Shah, B., Pillinger, M. H. & Krasnokutsky, S. Colchicine: old and new. Am. J. Med. 128, 461\u2013470 (2015).","journal-title":"Am. J. Med."},{"key":"1757_CR80","first-page":"251584142110277","volume":"13","author":"CJ Men","year":"2021","unstructured":"Men, C. J., Kossler, A. L. & Wester, S. T. Updates on the understanding and management of thyroid eye disease. Ther. Adv. Ophthalmol. 13, 25158414211027760 (2021).","journal-title":"Ther. Adv. Ophthalmol."},{"key":"1757_CR81","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.07.015","volume":"167","author":"M Pruenster","year":"2016","unstructured":"Pruenster, M., Vogl, T., Roth, J. & Sperandio, M. S100A8\/A9: from basic science to clinical application. Pharmacol. Ther. 167, 120\u2013131 (2016).","journal-title":"Pharmacol. Ther."},{"key":"1757_CR82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/09273948.2018.1547835","volume":"28","author":"JW Kim","year":"2020","unstructured":"Kim, J. W., Ko, J., Kim, J. & Yoon, J. S. Proinflammatory effects of calprotectin in Graves\u2019 orbitopathy. Ocul. Immunol. Inflamm. 28, 156\u2013163 (2020).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1757_CR83","doi-asserted-by":"publisher","first-page":"108813","DOI":"10.1016\/j.exer.2021.108813","volume":"213","author":"H Khazaei","year":"2021","unstructured":"Khazaei, H. et al. The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves\u2019 ophthalmopathy. Exp. Eye Res. 213, 108813 (2021).","journal-title":"Exp. Eye Res."},{"key":"1757_CR84","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41385-022-00551-6","volume":"15","author":"CS de Paiva","year":"2022","unstructured":"de Paiva, C. S., St. Leger, A. J. & Caspi, R. R. Mucosal immunology of the ocular surface. Mucosal Immunol. 15, 1143\u20131157 (2022).","journal-title":"Mucosal Immunol."},{"key":"1757_CR85","doi-asserted-by":"crossref","unstructured":"Bhardwaj, S. et al. Integrating the analysis of human biopsies using post-translational modifications proteomics. Protein Sci. 33, e4979 (2024).","DOI":"10.1002\/pro.4979"},{"key":"1757_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.66.14.11","volume":"66","author":"R Li","year":"2025","unstructured":"Li, R. et al. High-throughput tear proteomics reveals multi-faceted signatures of thyroid eye disease. Invest. Ophthalmol. Vis. Sci. 66, 11 (2025).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR87","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.7150\/ijbs.103977","volume":"20","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Multi-omics approaches to discover biomarkers of thyroid eye disease: a systematic review. Int. J. Biol. Sci. 20, 6038\u20136055 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"1757_CR88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.64.11.13","volume":"64","author":"HJ Byeon","year":"2023","unstructured":"Byeon, H. J. et al. The role of adipsin, complement factor D, in the pathogenesis of Graves\u2019 orbitopathy. Invest. Ophthalmol. Vis. Sci. 64, 13 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1757_CR89","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/labinvest.2011.189","volume":"92","author":"Y-T Chen","year":"2012","unstructured":"Chen, Y.-T. et al. Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sj\u00f6gren\u2019s syndrome. Lab. Invest. 92, 556\u2013570 (2012).","journal-title":"Lab. Invest."},{"key":"1757_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35564-z","volume":"13","author":"T V\u00e4likangas","year":"2022","unstructured":"V\u00e4likangas, T. et al. Benchmarking tools for detecting longitudinal differential expression in proteomics data allows establishing a robust reproducibility optimization regression approach. Nat. Commun. 13, 7877 (2022).","journal-title":"Nat. Commun."},{"key":"1757_CR91","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/bioinformatics\/btab664","volume":"38","author":"A Bodein","year":"2022","unstructured":"Bodein, A., Scott-Boyer, M.-P., Perin, O., L\u00ea, Cao, K.-A. & Droit, A. timeOmics: an R package for longitudinal multi-omics data integration. Bioinformatics 38, 577\u2013579 (2022).","journal-title":"Bioinformatics"},{"key":"1757_CR92","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1213\/ANE.0000000000003511","volume":"127","author":"P Schober","year":"2018","unstructured":"Schober, P. & Vetter, T. R. Repeated measures designs and analysis of longitudinal data: if at first you do not succeed-try, try again: if at first you do not succeed-try, try again. Anesth. Analg. 127, 569\u2013575 (2018).","journal-title":"Anesth. Analg."},{"key":"1757_CR93","doi-asserted-by":"publisher","first-page":"e013096","DOI":"10.1136\/bmjopen-2016-013096","volume":"6","author":"CJ Coffman","year":"2016","unstructured":"Coffman, C. J., Edelman, D. & Woolson, R. F. To condition or not condition? Analysing \u2018change\u2019 in longitudinal randomised controlled trials. BMJ Open 6, e013096 (2016).","journal-title":"BMJ Open"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01757-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01757-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:04:24Z","timestamp":1792541064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01757-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01757-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.K. is a consultant for Amgen (consultant, independent contractor), Immunovant (consultant\/advisor), Viridian (consultant, independent contractor), Sling Therapeutics (independent contractor), Genentech (consultant), Kriya (consultant), Aceylrin (consultant, independent contractor), Argenx (consultant), Lassen (consultant, independent contractor). The funding organizations had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"547"}}